{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:05:48Z","timestamp":1790910348977,"version":"4.1.0"},"reference-count":54,"publisher":"Harborside Press, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Venous thromboembolism (VTE) is a major complication in all patients with cancer. Compared with the general population, patients with multiple myeloma (MM) have a 9-fold increase in VTE risk, likely because of their malignancy, its treatments, and other additional patient-related factors. In MM, thromboembolism events tend to occur within 6 months of treatment initiation, regardless of treatment regimen; however, the use of immunomodulatory agents such as thalidomide or lenalidomide, especially in combination with dexamethasone or multiagent chemotherapy, is known to create a significant risk for VTE. Currently, official recommendations for VTE prophylaxis in MM outlined in various national guidelines or multidisciplinary society panels are based on expert opinion, because data from randomized controlled trials are scarce. Large studies which have mainly focused on the efficacy of thromboprophylaxis in patients with cancer at higher risk for VTE either had a very low representation of patients with MM, or excluded them all together, limiting our ability to draw evidence-based conclusions on how to effectively protect MM population from VTE. In this brief perspective, we highlight some of the greatest challenges that have hampered the field concerning the availability of high-quality clinical trial data for the formulation of best VTE prophylaxis strategies in patients with newly diagnosed MM, as well as the rationale for the latest updates in the NCCN Guidelines on this topic.<\/jats:p>","DOI":"10.6004\/jnccn.2021.7112","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T14:45:24Z","timestamp":1643381124000},"page":"91-95","source":"Crossref","is-referenced-by-count":12,"title":["Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma"],"prefix":"10.6004","volume":"20","author":[{"given":"Muhamed","family":"Baljevic","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Hematologic Malignancies, University of Utah, Huntsman Cancer, Salt Lake City, Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Y.","family":"Lim","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Hematologic Malignancies, University of Utah, Huntsman Cancer, Salt Lake City, Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[{"name":"3Roswell Park Comprehensive Cancer Center, Buffalo, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"4UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"5Dana-Farber\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Streiff","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Medicine and Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"7Mayo Clinic Cancer Center, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[{"name":"8University of Wisconsin Carbone Cancer Center, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref531","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/S2152-2650(21)02307-7","article-title":"Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in newly diagnosed multiple myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study [abstract]","volume":"21","author":"Sborov","year":"2021","journal-title":"Clin Lymphoma Myeloma"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.2020009029","article-title":"Bradbury CA, Craig Z, Cook G, et al. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood. 2020;136(9):1091-1104","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-142762","article-title":"D-dimer improves risk prediction of venous thromboembolism in patients with multiple myeloma [abstract]","volume":"136","author":"Sanfilippo","year":"2020","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S0049-3848(20)30401-1","article-title":"Assessing the risk of venous thromboembolism in multiple myeloma","volume":"191","author":"Sanfilippo","year":"2020","journal-title":"Thromb Res"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/pds.4180","article-title":"Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database","volume":"26","author":"Palmaro","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"E191","DOI":"10.3390\/cancers12010191","article-title":"Multiple myeloma and thrombosis: prophylaxis and risk prediction tools","volume":"12","author":"Fotiou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.2020009029","article-title":"Bradbury CA, Craig Z, Cook G, et al. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood. 2020;136(9):1091-1104","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.6004\/jnccn.2018.0084","article-title":"NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018","volume":"16","author":"Streiff","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"ref251","first-page":"553","article-title":"Thrombotic events in patients with myeloma treated with immunomodulatory drugs; results of the Myeloma XI study [abstract]","volume":"130","author":"Bradbury","year":"2017","journal-title":"Blood"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"E191","DOI":"10.3390\/cancers12010191","article-title":"Multiple myeloma and thrombosis: prophylaxis and risk prediction tools","volume":"12","author":"Fotiou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cam4.1927","article-title":"Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation","volume":"8","author":"Baker","year":"2019","journal-title":"Cancer Med"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/S2152-2650(21)02307-7","article-title":"Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in newly diagnosed multiple myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study [abstract]","volume":"21","author":"Sborov","year":"2021","journal-title":"Clin Lymphoma Myeloma"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-142762","article-title":"D-dimer improves risk prediction of venous thromboembolism in patients with multiple myeloma [abstract]","volume":"136","author":"Sanfilippo","year":"2020","journal-title":"Blood"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S0049-3848(20)30401-1","article-title":"Assessing the risk of venous thromboembolism in multiple myeloma","volume":"191","author":"Sanfilippo","year":"2020","journal-title":"Thromb Res"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cam4.1927","article-title":"Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation","volume":"8","author":"Baker","year":"2019","journal-title":"Cancer Med"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"ref551","first-page":"553","article-title":"Thrombotic events in patients with myeloma treated with immunomodulatory drugs; results of the Myeloma XI study [abstract]","volume":"130","author":"Bradbury","year":"2017","journal-title":"Blood"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.6004\/jnccn.2018.0084","article-title":"NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018","volume":"16","author":"Streiff","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/pds.4180","article-title":"Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database","volume":"26","author":"Palmaro","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/1\/article-p91.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/1\/article-p91.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T18:09:56Z","timestamp":1645812596000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/1\/article-p91.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":54,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2021.7112","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}